BI 771716

BI 771716 is an investigational antibody fragment developed for the treatment of geographic atrophy (GA), a severe and advanced form of dry age-related macular degeneration (AMD). The drug is engineered using proprietary technology from CDR-Life and developed by Boehringer Ingelheim. Its unique design as a highly specific antibody fragment allows for optimized penetration through all retinal layers, targeting the critical sites driving GA pathology. Administered via intravitreal injection, BI 771716 aims to preserve vision by addressing the underlying causes of GA. Clinical trials have demonstrated favorable safety and tolerability profiles in both single and multiple dose regimens, with ongoing Phase II studies evaluating its efficacy in patients with GA.